BORIANI, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 118.113
EU - Europa 58.624
AS - Asia 46.612
SA - Sud America 8.067
Continente sconosciuto - Info sul continente non disponibili 3.252
AF - Africa 911
OC - Oceania 400
Totale 235.979
Nazione #
US - Stati Uniti d'America 115.647
SE - Svezia 21.007
SG - Singapore 14.325
GB - Regno Unito 11.059
CN - Cina 11.011
IT - Italia 8.395
BR - Brasile 6.595
HK - Hong Kong 6.382
VN - Vietnam 4.611
DE - Germania 3.434
PL - Polonia 3.169
FI - Finlandia 3.167
BD - Bangladesh 2.820
TR - Turchia 2.086
UA - Ucraina 1.917
RU - Federazione Russa 1.682
FR - Francia 1.656
KR - Corea 1.197
CA - Canada 1.014
BG - Bulgaria 895
IN - India 769
ID - Indonesia 640
NL - Olanda 526
JP - Giappone 477
AR - Argentina 474
MX - Messico 411
BZ - Belize 403
AU - Australia 377
IQ - Iraq 365
ES - Italia 282
AE - Emirati Arabi Uniti 271
IE - Irlanda 262
AT - Austria 252
PK - Pakistan 244
ZA - Sudafrica 225
CO - Colombia 222
EC - Ecuador 205
VE - Venezuela 170
UZ - Uzbekistan 155
MA - Marocco 148
JM - Giamaica 141
CL - Cile 136
MY - Malesia 130
LT - Lituania 117
PH - Filippine 111
CR - Costa Rica 110
SA - Arabia Saudita 107
CZ - Repubblica Ceca 103
EG - Egitto 98
JO - Giordania 98
BE - Belgio 96
KE - Kenya 96
NP - Nepal 91
TH - Thailandia 81
TN - Tunisia 81
AZ - Azerbaigian 78
CH - Svizzera 77
RO - Romania 77
DZ - Algeria 73
PY - Paraguay 73
TW - Taiwan 73
IL - Israele 67
PE - Perù 65
BO - Bolivia 64
UY - Uruguay 59
KZ - Kazakistan 53
TT - Trinidad e Tobago 53
HN - Honduras 51
PT - Portogallo 50
RS - Serbia 49
GE - Georgia 46
DO - Repubblica Dominicana 45
GR - Grecia 45
IR - Iran 45
GT - Guatemala 42
OM - Oman 39
BY - Bielorussia 37
EU - Europa 36
NI - Nicaragua 35
PR - Porto Rico 34
AL - Albania 33
DK - Danimarca 32
HR - Croazia 32
SN - Senegal 30
LB - Libano 28
PA - Panama 28
SV - El Salvador 27
KG - Kirghizistan 26
BH - Bahrain 25
ET - Etiopia 25
PS - Palestinian Territory 24
QA - Qatar 24
HU - Ungheria 23
SI - Slovenia 22
BA - Bosnia-Erzegovina 21
SK - Slovacchia (Repubblica Slovacca) 21
MD - Moldavia 19
NZ - Nuova Zelanda 19
AO - Angola 18
NG - Nigeria 18
Totale 232.404
Città #
Stockholm 18.329
Fairfield 12.858
Ashburn 11.982
Singapore 9.215
Santa Clara 7.983
Woodbridge 7.528
Southend 7.258
Hong Kong 6.210
Houston 5.988
Seattle 5.025
San Jose 4.748
Cambridge 4.161
Wilmington 4.159
Chandler 4.147
Jacksonville 3.693
Hefei 3.258
Warsaw 3.014
Helsinki 2.824
Ann Arbor 2.816
London 2.628
Council Bluffs 2.495
Dearborn 2.335
Beijing 2.080
New York 1.984
The Dalles 1.767
Los Angeles 1.593
Modena 1.543
Nyköping 1.463
Ho Chi Minh City 1.416
San Diego 1.264
Chicago 1.230
Izmir 1.225
Seoul 1.152
Columbus 1.144
Hanoi 1.140
Milan 1.000
Dallas 918
Princeton 896
Sofia 865
Lauterbourg 792
Buffalo 755
Eugene 730
Moscow 534
São Paulo 531
Jakarta 478
Boardman 470
Rome 457
Shanghai 449
Belize City 400
Atlanta 393
Salt Lake City 383
Bologna 339
Tokyo 310
Munich 273
Da Nang 267
Toronto 260
Falls Church 257
Dublin 239
Frankfurt am Main 226
North Bergen 224
Nuremberg 224
Rio de Janeiro 212
Haiphong 211
Phoenix 208
Amsterdam 206
Las Vegas 206
Naples 200
Fremont 193
Redondo Beach 191
Brooklyn 181
Guangzhou 180
Orem 172
Perth 170
Saint Louis 169
Norwalk 168
Montreal 157
Belo Horizonte 156
Miano 156
Tampa 153
Kent 152
Philadelphia 150
Albuquerque 148
San Francisco 147
Lappeenranta 145
Tashkent 140
Elk Grove Village 135
Baghdad 132
Kunming 132
Denver 124
Miami 123
Nanjing 120
Redwood City 120
Johannesburg 119
Mexico City 118
Florence 115
Brasília 114
Charlotte 110
Curitiba 106
Kilburn 100
Turin 100
Totale 170.264
Nome #
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 2.656
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.515
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 2.472
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 2.423
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 2.176
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 2.108
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.101
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 2.088
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 2.083
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 2.081
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 722
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 670
Determinants of all-cause mortality in different age groups in patients with severe systolic left ventricular dysfunction receiving an implantable cardioverter defibrillator (from the Italian ClinicalService Multicenter Observational Project) 642
La sindrome da pacemaker. 621
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 617
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) 608
A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. 543
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 543
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 529
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 511
Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies 510
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 507
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 501
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation 452
A prospective randomized evaluation of VV delay optimization in CRT patients. Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques 443
Nightmares and sleep disturbances with simvastatin and metoprolol 412
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 410
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 399
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 386
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 370
Radar-Based Monitoring of Vital Signs: A Tutorial Overview 365
A CONTROLLED-STUDY ON ORAL PROPAFENONE VERSUS DIGOXIN PLUS QUINIDINE IN CONVERTING RECENT-ONSET ATRIAL-FIBRILLATION TO SINUS RHYTHM 359
Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 358
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 357
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 357
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 356
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 355
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 354
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 353
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 353
Atrial fibrillation: Adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. 352
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 350
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 346
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 345
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 344
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 343
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 343
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 339
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) 336
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing) 336
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA) 335
Oral anticoagulants in patients with atrial fibrillation and end-stage renal disease: Walking the tightrope between thromboembolic and bleeding risk 324
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 324
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 319
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 318
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics 315
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 314
Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes 314
Clinically guided pacemaker choice and setting: pacemaker expert programming study 313
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 313
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 313
Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry 313
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 312
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 311
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA 311
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 310
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis 309
Holter ECG for pacemaker/defibrillator carriers: What is its role in the era of remote monitoring? 307
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 307
Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 307
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 305
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 305
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 303
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 303
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 302
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 302
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 302
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 302
The wearable cardioverter-defibrillator: Current technology and evolving indications 301
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 300
Heart failure after myocardial revascularization: Risk markers 299
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 299
Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection 298
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 295
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 295
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 295
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 294
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry 294
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 293
Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers 293
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 292
Drug management of atrial fibrillation in light of guidelines and current evidence: an Italian Survey on behalf of Italian Association of Arrhythmology and Cardiac Pacing 291
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 290
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy 290
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 290
EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA) 289
Health economics and the European Heart Rhythm Association. 289
The 2024 ESC guidelines on atrial fibrillation: essential updates for everyday clinical practice 287
Asymptomatic vs. symptomatic atrial fibrillation: Clinical outcomes in heart failure patients 287
DIGItal Health Literacy after COVID-19 Outbreak among Frail and Non-Frail Cardiology Patients: The DIGI-COVID Study 287
Totale 55.261
Categoria #
all - tutte 896.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 896.270


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202212.953 0 0 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202533.713 1.151 386 730 1.788 4.911 5.146 3.766 2.148 4.150 2.542 3.045 3.950
2025/202683.486 3.554 1.887 5.259 4.812 5.374 9.122 9.842 3.735 24.539 4.807 5.986 4.569
2026/202712.202 3.158 5.320 3.724 0 0 0 0 0 0 0 0 0
Totale 235.979